Polyvalent immunoglobulins : Part 1: A rapid review

129 p.ill.,SCIENTIFIC REPORT 7 -- 1 INTRODUCTION 7 -- 1.1 BACKGROUND 7 -- 1.2 INTERNATIONAL CONTEXT 7 -- 1.4 PROJECT SCOPE .13 -- 2 THE EFFECTIVENESS AND SAFETY OF IMMUNOGLOBULINS BY INDICATION 13 -- 2.1 BACKGROUND 13 -- 2.2 METHODS 14 -- 2.2.1 Overview of general methodology 14 -- 2.2.2 Literature search and selection of indications 17 -- 2.2.3 Quality appraisal and data extraction .18 -- 2.2.4 Assessing efficacy 18 -- 2.2.5 Assessing safety 18 -- 2.3.1 General Safety 21 -- 2.3.2 Indication-specific results - Reimbursed indications 23 -- 2.3.3 Indication-specific results - Commonly recommended indications in other countries 52 -- 2.3.4 Other indications for which evidence exists 66 -- 2.3.5 Ongoing trials .70 -- 3 SYSTEMATIC LITERATURE REVIEW OF ECONOMIC STUDIES 77 -- 3.1 INTRODUCTION .77 -- 3.2 METHODS 77 -- 3.2.1 Search strategy .77 -- 3.2.2 Selection procedure 77 -- 3.2.3 Selection criteria 77 -- 3.3 OVERVIEW OF ECONOMIC EVALUATIONS .80 -- 3.3.1 Type of economic evaluation .81 -- 3.3.2 Time frame of analyses and discounting .81 -- 3.3.3 Perspective .81 -- 3.3.4 Indications and Population 81 -- 3.3.5 Comparators 81 -- 3.3.6 Cost and outcome inputs .82 -- 3.3.7 Modelling 82 -- 3.3.8 Results 83 -- 3.3.9 Sensitivity analysis 91 -- 3.3.10 Conflict of interest 91 -- 3.4 DISCUSSION AND CONCLUSIONS 91 -- 4 HOW DO THE INDICATIONS REIMBURSED IN BELGIUM COMPARE TO INDICATIONS REIMBURSED IN OTHER COUNTRIES? 93 -- 4.1 METHODS 93 -- 4.2 BELGIUM 93 -- 4.3 AUSTRALIA 94 -- 4.4 FRANCE 95 -- 4.5 CANADA 96 -- 4.6 ENGLAND 99 -- 4.7 INTERPRETATION INTERNATIONAL: 100 -- 5 DISCUSSION AND CONCLUSIONS .104 -- 5.1 DISCUSSION .104 -- 5.2 CONCLUSIONS 107 -- REFERENCES 10